Hepatocellular cancer in HIV-infected individuals: tomorrow’s problem?

References

• Grulich AE. Update: cancer risk in persons with HIV/AIDS in the era of combination antiretroviral therapy. AIDS Read.10(6), 341–346 (2000).
   PubMedGoogle Scholar
• Gingues S, Gill MJ. The impact of highly active antiretroviral therapy on the incidence and outcomes of AIDS-defining cancers in Southern Alberta. HIV Med.7(6), 369–377 (2006).
   PubMed Web of Science ®Google Scholar
• Frisch M, Biggar RJ, Engels EA, Goedert JJ; AIDS-Cancer Match Registry Study Group. Association of cancer with AIDS-related immunosuppression in adults. JAMA285(13), 1736–1745 (2001).
   PubMed Web of Science ®Google Scholar
• Mbulaiteye SM, Parkin DM, Rabkin CS. Epidemiology of AIDS-related malignancies an international perspective. Hematol. Oncol. Clin. North Am.17(3), 673–696 (2003).
   PubMed Web of Science ®Google Scholar
• Pantanowitz L, Schlecht HP, Dezube BJ. Growing problem of non-AIDS-defining malignancies in HIV. Curr. Opin. Oncol.18(5), 469–478 (2006).
   PubMed Web of Science ®Google Scholar
• Anthony PP. Hepatocellular carcinoma: an overview. Histopathology39, 109–118 (2001).
   PubMed Web of Science ®Google Scholar
• Chen CJ, Yang HI, Su J. Risk of hepatocellular carcinoma across a biological gradient of serum hepatitis B virus DNA level. JAMA295, 65–73 (2006).
   PubMed Web of Science ®Google Scholar
• Chen G, Lin W, Shen F, Iloeje UH, London WT, Evans AA. Past HBV viral load as predictor of mortality and morbidity from HCC and chronic liver disease in a prospective study. Am. J. Gastroenterol.101(8), 1797–1803 (2006).
   PubMed Web of Science ®Google Scholar
• Toyoda H. Long-term follow-up of sustained responders to interferon therapy, in patients with chronic hepatitis C. J. Viral Hepat.7(6), 414–419 (2000).
   PubMed Web of Science ®Google Scholar
• Szabo E, Paska C, Kaposi Novak P, Schaff Z, Kiss A. Similarities and differences in hepatitis B and C virus induced hepatocarcinogenesis. Pathol. Oncol. Res.10(1), 5–11 (2004).
   PubMed Web of Science ®Google Scholar
• Andrisani OM, Baranabas S. The transcriptional function of hepatitis B virus protein x and its role in hepatocarcinogenesis. Int. J. Oncol.15, 373–379 (1999).
   PubMed Web of Science ®Google Scholar
• Okuda M, Li K, Beard MR et al. Mitochondrial injury, oxidative stress, and antioxidant gene expression are induced by hepatitis C virus core protein. Gastroenterology122(2), 366–375 (2002).
   PubMed Web of Science ®Google Scholar
• Chemin I, Trepo C. Clinical impact of occult HBV infections. J. Clin. Virol.34(Suppl. 1), S15–S21 (2005).
   Google Scholar
• Mphahlele MJ, Lukhwareni A, Burnett RJ, Moropeng LM, Ngobeni JM. High risk of occult hepatitis B virus infection in HIV-positive patients from South Africa.J. Clin. Virol.35(1), 14–20 (2006).
   PubMed Web of Science ®Google Scholar
• Shiota G, Oyama K, Udagawa A et al. Occult hepatitis B virus infection in HBs antigen-negative hepatocellular carcinoma in a Japanese population: involvement of HBx and p53.J. Med. Virol.62(2), 151–158 (2000).
   PubMed Web of Science ®Google Scholar
• Higashi Y, Tada S, Miyase S et al. Correlation of clinical characteristics with detection of hepatitis B virus X gene in liver tissue in HBsAg-negative, and HCV-negative hepatocellular carcinoma patients. Liver22(5), 374–379 (2002).
   PubMedGoogle Scholar
• Pollicino T, Squadrito G, Cerenzia G et al. Hepatitis B virus maintains its pro-oncogenic properties in the case of occult HBV infection. Gastroenterology126(1), 102–110 (2004).
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Kurbanov F, Mano S et al. Molecular tracing of the global hepatitis C virus epidemic predicts regional patterns of hepatocellular carcinoma mortality. Gastroenterology130(3), 703–714 (2006).
   PubMed Web of Science ®Google Scholar
• Thomas DL, Astemborski J, Rai RM et al. The natural history of hepatitis C virus infection: host, viral, and environmental factors. JAMA284(4), 450–456 (2000).
   PubMed Web of Science ®Google Scholar
• Smukler AJ, Ratner L. Hepatitis viruses and hepatocellular carcinoma in HIV-infected patients. Curr. Opin. Oncol.14(5), 538–542 (2002).
   PubMed Web of Science ®Google Scholar
• Bruno R, Gazzaruso C, Sacchi P et al. High prevalence of metabolic syndrome among HIV-infected patients: link with the cardiovascular risk. J. Acquir. Immune Defic. Syndr.31(3), 363–365 (2002).
   PubMed Web of Science ®Google Scholar
• Thio CL, Seaberg EC, Skolasky R Jr et al. HIV-1, hepatitis B virus, and risk of liver-related mortality in the Multicenter Cohort Study (MACS). Lancet360, 1921–1926 (2002).
   PubMed Web of Science ®Google Scholar
• Shire NJ, Rouster SD, Rajicic N, Sherman KE. Occult hepatitis B in HIV-infected patients. J. Acquir. Immune Defic. Syndr.36(3), 869–875 (2004).
   PubMed Web of Science ®Google Scholar
• Hyun CB, Coyle WJ. Hepatocellular carcinoma in a patient with human immunodeficiency virus and hepatitis B virus coinfection: an emerging problem? South Med. J.97(4), 401–406 (2004).
   PubMed Web of Science ®Google Scholar
• Puoti M, Bruno R, Soriano V et al. HIV HCC Cooperative Italian-Spanish Group. Hepatocellular carcinoma in HIV-infected patients: epidemiological features, clinical presentation and outcome. AIDS18(17), 2285–2293 (2004).
   PubMed Web of Science ®Google Scholar
• Salmon-Ceron D, Lewden C, Morlat P et al. The Mortality (2000) study group. Liver disease as a major cause of death among HIV infected patients: role of hepatitis C and B viruses and alcohol. J. Hepatol.42(6), 799–805 (2005).
   PubMed Web of Science ®Google Scholar
• Altavilla G, Caputo A, Lanfredi M, Piola C, Barbanti-Brodano G. Enhancement of chemical hepatocarcinogenesis by the HIV-1 tat gene. Am. J. Pathol.157(4), 1081–1089 (2000).
   PubMed Web of Science ®Google Scholar
• Hyun CB, Coyle WJ. Related hepatocellular carcinoma in a patient with human immunodeficiency virus and hepatitis B virus coinfection: an emerging problem? South Med. J.97(4), 401–406 (2004).
   PubMed Web of Science ®Google Scholar
• Powles T, Nelson M, Bower M. HIV-related lung cancer – a growing concern? Int. J. STD AIDS14(10), 647–651 (2003).
   PubMed Web of Science ®Google Scholar
• Prakash O, Mason A, Luftig RB, Bautista AP. Hepatitis C virus (HCV) and human immunodeficiency virus type 1 (HIV-1) infections in alcoholics. Front. Biosci.7, E286–E300 (2002).
   PubMed Web of Science ®Google Scholar
• Mbulaiteye SM, Biggar RJ, Goedert JJ, Engels EA. Immune deficiency and risk for malignancy among persons with AIDS. J. Acquir. Immune Defic. Syndr.32(5), 527–533 (2003).
   PubMed Web of Science ®Google Scholar
• Kramer JR, Giordano TP, Souchek J, Richardson P, Hwang LY, El-Serag HB. The effect of HIV coinfection on the risk of cirrhosis and hepatocellular carcinoma in U.S. veterans with hepatitis C. Am. J. Gastroenterol.100(1), 56–63 (2005).
   PubMed Web of Science ®Google Scholar
• Giordano TP, Kramer JR, Souchek J, Richardson P, El-Serag HB. Cirrhosis and hepatocellular carcinoma in HIV-infected veterans with and without the hepatitis C virus: a cohort study, 1992–2001. Arch. Intern. Med.164(21), 2349–2354 (2004).
   PubMedGoogle Scholar
• Clifford GM, Polesel J, Rickenbach M et al. Swiss HIV Cohort. Cancer risk in the Swiss HIV Cohort Study: associations with immunodeficiency, smoking, and highly active antiretroviral therapy. J. Natl Cancer Inst.97(6), 425–432 (2005).
   PubMed Web of Science ®Google Scholar
• Herida M, Mary-Krause M, Kaphan R et al. Incidence of non-AIDS-defining cancers before and during the highly active antiretroviral therapy era in a cohort of human immunodeficiency virus-infected patients. J. Clin. Oncol.21(18), 3447–3453 (2003).
   PubMed Web of Science ®Google Scholar
• Lewden C, Salmon D, Morlat P et al. Mortality (2000) study group. Causes of death among human immunodeficiency virus (HIV)-infected adults in the era of potent antiretroviral therapy: emerging role of hepatitis and cancers, persistent role of AIDS. Int. J. Epidemiol.34(1), 121–130 (2005).
   PubMed Web of Science ®Google Scholar
• Rosenthal E, Poiree M, Pradier C et al. Mortality due to hepatitis C-related liver disease in HIV-infected patients in France. AIDS17(12), 1803–1809 (2003).
   PubMed Web of Science ®Google Scholar
• Llovet JM, Burroughs A, Bruix J. Hepatocellular carcinoma. Lancet362(9399), 1907–1917 (2003).
   PubMed Web of Science ®Google Scholar
• Bruix J, Sherman M, Llovet JM et al. EASL Panel of Experts on HCC. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J. Hepatol.35(3), 421–430 (2001).
   PubMed Web of Science ®Google Scholar
• Powles T, Bower M, Daugaard G et al. Multicenter study of human immunodeficiency virus-related germ cell tumors. J. Clin. Oncol.21(10), 1922–1927 (2003).
   PubMed Web of Science ®Google Scholar
• Ettorre GM, Vennarecci G, Boschetto A et al. Resection and transplantation: evaluation of surgical perspectives in HIV positive patients affected by end-stage liver disease. J. Exp. Clin. Cancer Res.22(4 Suppl.), 167–169 (2003).
   PubMed Web of Science ®Google Scholar
• Ragni MV, Belle SH, Im K et al. Survival of human immunodeficiency virus-infected liver transplant recipients. J. Infect. Dis.188(10), 1412–1420 (2003).
   PubMed Web of Science ®Google Scholar
• Klassen MK, Lewin-Smith M, Frankel SS, Nelson AM. Pathology of human immunodeficiency virus infection: noninfectious conditions. Ann. Diagn. Pathol.1(1), 57–64 (1997).
   PubMedGoogle Scholar
• Neff GW, Bonham A, Tzakis AG et al. Orthotopic liver transplantation in patients with human immunodeficiency virus and end-stage liver disease. Liver Transpl.9(3), 239–247 (2003).
   PubMed Web of Science ®Google Scholar
• Roland ME, Stock PG. Liver transplantation in HIV-infected recipients. Semin. Liver Dis.26(3), 273–284 (2006).
   PubMed Web of Science ®Google Scholar
• Di Benedetto F, De Ruvo N, Berretta M et al. Don’t deny liver transplantation to HIV patients with hepatocellular carcinoma in the highly active antiretroviral therapy era. J. Clin. Oncol.24(14), E26–E27 (2006).
   Google Scholar
• Hughes CA, Shafran SD. Treatment of hepatitis C in HIV-coinfected patients. Ann. Pharmacother.40(3), 479–489 (2006).
   PubMed Web of Science ®Google Scholar
• Chung RT. Hepatitis C and B viruses: the new opportunists in HIV infection.Top. HIV Med.14(2), 78–83 (2006).
   PubMedGoogle Scholar
• Ockenga J, Tillmann HL, Trautwein C, Stoll M, Manns MP, Schmidt RE. Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. J. Hepatol.27(1), 18–24 (1997).
   PubMed Web of Science ®Google Scholar
• Dimitrakopoulos A, Takou A, Haida A, Molangeli S, Gialeraki A, Kordossis T. The prevalence of hepatitis B and C in HIV-positive Greek patients: relationship to survival of deceased AIDS patients. J. Infect.40(2), 127–131 (2000).
   PubMed Web of Science ®Google Scholar
• Sungkanuparph S, Vibhagool A, Manosuthi W et al. Prevalence of hepatitis B virus and hepatitis C virus co-infection with human immunodeficiency virus in Thai patients: a tertiary-care-based study. J. Med. Assoc. Thai.87(11), 1349–1354 (2004).
   PubMedGoogle Scholar
• Gonzalez-Garcia JJ, Mahillo B, Hernandez S et al. Prevalences of hepatitis virus coinfection and indications for chronic hepatitis C virus treatment and liver transplantation in Spanish HIV-infected patients. The GESIDA 29/02 and FIPSE 12185/01 Multicenter Study. Enferm. Infec. Microbiol. Clin.23(6), 340–348 (2005).
   PubMed Web of Science ®Google Scholar
• Lincoln D, Petoumenos K, Dore GJ; Australian HIV Observational Database. HIV/HBV and HIV/HCV coinfection, and outcomes following highly active antiretroviral therapy. HIV Med.4(3), 241–249 (2003).
   PubMedGoogle Scholar
• Rouet F, Chaix ML, Inwoley A et al. ANRS (1236) DITRAME-B&C Study Group. HBV and HCV prevalence and viraemia in HIV-positive and HIV-negative pregnant women in Abidjan, Cote d’Ivoire: the ANRS (1236) study. J. Med. Virol.74(1), 34–40 (2004).
   PubMed Web of Science ®Google Scholar